Fair Accountability and Innovative Research Drug Pricing Act of 2021
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Fair Accountability and Innovative Research Drug Pricing Act of 2021
This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-S-898/
"S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-898/.
S. 898, 117th Cong. (2026), https://openamerica.io/bill/117-S-898/.
[S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021](https://openamerica.io/bill/117-S-898/)